AmgenSTU:AMG +0.24%87 FCF Margin % is 17.14% as of Mar. 2026, which is 51% below its 10-year median of 34.95. GuruFocus rates STU:AMG with a GF Score™ of 87/100 and a GF Value™ of €310.99 (Fairly Valued). The stock has 6 warning signs investors should review. Among 958 Drug Manufacturers companies, Amgen ranks better than 92.28% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Amgen's Free Cash Flow for the
three
months ended in Mar. 2026 was €1,278 Mil. Amgen's Revenue for the
three
months ended in Mar. 2026 was €7,455 Mil. Therefore, Amgen's FCF Margin % for the quarter that ended in Mar. 2026 was 17.14%.
The historical rank and industry rank for Amgen's FCF Margin % or its related term are showing as below:
STU:AMG'
s FCF Margin % Range Over the Past 10 Years
Min: 22.04 Med: 34.95 Max: 46.01
Current: 23.06
During the past 13 years, the highest FCF Margin % of Amgen was 46.01%. The lowest was 22.04%. And the median was 34.95%.
STU:AMG's FCF Margin % is ranked better than 92.28% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs STU:AMG: 23.06
Amgen FCF Margin % Related Terms
Amgen FCF Margin % Historical Data
* Premium members only.
The historical data trend for Amgen's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AMG vs GILD, PFE, BMY: FCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Amgen's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Amgen's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen (STU:AMG) has a FCF Margin % of 17.14% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Amgen and its competitors. This is 51% below median its historical median of 34.95. Over the past decade, Amgen's FCF Margin % has ranged from 22.04 to 46.01. According to the industry distribution chart, Amgen ranks #74 out of 958 companies in the Drug Manufacturers industry, placing it in the top 7.7%.
Is Amgen's FCF Margin % too high?
Amgen's current FCF Margin % of 17.14% is 51% below median its 10-year median of 34.95. Over the past 10 years, this metric has ranged from a low of 22.04 to a high of 46.01. The Drug Manufacturers industry median FCF Margin % is 2.45. Amgen's value of 17.14% is 601% above this industry median. Based on the distribution chart, Amgen ranks #74 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Amgen has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amgen's FCF Margin % compare to GILD and PFE?
According to the Drug Manufacturers industry distribution chart, Amgen ranks #74 out of 958 companies for FCF Margin %. This places Amgen in the top 8% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.45. Amgen's value of 17.14% is 601% above this benchmark. Historically, Amgen's own FCF Margin % has ranged from 22.04 to 46.01 over the past decade. While the company's 10-year median is 34.95 vs. the industry median of 2.45, Amgen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amgen's current FCF Margin % of 17.14% is 601% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Amgen and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amgen's current FCF Margin % is 17.14%, which is 51% below median its own 10-year median of 34.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (STU:AMG) is currently considered Fairly Valued. The stock's GF Value™ is €310.99, compared to a current price of €310.35 — trading 0.2% below its estimated fair value. The current FCF Margin % is 17.14%, which is 51% below median its 10-year median of 34.95 and 601% above the Drug Manufacturers industry median of 2.45. Amgen's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Amgen (STU:AMG), the current FCF Margin % is 17.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amgen (STU:AMG) Overvalued in 2026?
Based on GuruFocus' analysis, Amgen stock appears to be undervalued.
The current stock price of €310.35 is trading 0.2% below its estimated GF Value™ of €310.99.
GuruFocus considers Amgen to be Fairly Valued.
Key valuation signals for STU:AMG:
FCF Margin %: 17.14% (51% below median its 10-year median of 34.95)
GF Value™: €310.99 vs. price of €310.35 (0.2% below fair value)
Industry Position: 601% above the Drug Manufacturers median (#74 of 958)
No single metric tells the full story. See the STU:AMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
87GF Score
Get the complete analysis for STU:AMG
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AMG has been successfully added to your 
